Boston Scientific (NYSE:BSX) touted one-year data today from an analysis of its Eluvia drug-eluting vascular stent system, showing that the device is safe and effective in patients with long, complex, calcified lesions.
The data were presented by Boston Scientific at the annual Vascular Interventional Advances meeting.
Get the full story at our sister site, Drug Delivery Business News.
The post Boston Scientific’s Eluvia drug-eluting stent succeeds in long lesions appeared first on MassDevice.